全文获取类型
收费全文 | 2931765篇 |
免费 | 251093篇 |
国内免费 | 13756篇 |
专业分类
耳鼻咽喉 | 40072篇 |
儿科学 | 92558篇 |
妇产科学 | 73365篇 |
基础医学 | 483338篇 |
口腔科学 | 76313篇 |
临床医学 | 266658篇 |
内科学 | 503036篇 |
皮肤病学 | 83487篇 |
神经病学 | 249788篇 |
特种医学 | 115712篇 |
外国民族医学 | 81篇 |
外科学 | 462896篇 |
综合类 | 89953篇 |
现状与发展 | 24篇 |
一般理论 | 2082篇 |
预防医学 | 249243篇 |
眼科学 | 66429篇 |
药学 | 197945篇 |
30篇 | |
中国医学 | 9544篇 |
肿瘤学 | 134060篇 |
出版年
2022年 | 23646篇 |
2021年 | 55844篇 |
2020年 | 35598篇 |
2019年 | 58479篇 |
2018年 | 71070篇 |
2017年 | 54062篇 |
2016年 | 59313篇 |
2015年 | 74102篇 |
2014年 | 108348篇 |
2013年 | 173495篇 |
2012年 | 79305篇 |
2011年 | 78401篇 |
2010年 | 114415篇 |
2009年 | 119080篇 |
2008年 | 64505篇 |
2007年 | 66310篇 |
2006年 | 76929篇 |
2005年 | 72616篇 |
2004年 | 74533篇 |
2003年 | 65733篇 |
2002年 | 55740篇 |
2001年 | 73207篇 |
2000年 | 64708篇 |
1999年 | 70833篇 |
1998年 | 62008篇 |
1997年 | 60438篇 |
1996年 | 58121篇 |
1995年 | 53575篇 |
1994年 | 47597篇 |
1993年 | 44639篇 |
1992年 | 47179篇 |
1991年 | 46370篇 |
1990年 | 43970篇 |
1989年 | 44183篇 |
1988年 | 40979篇 |
1987年 | 40128篇 |
1986年 | 37972篇 |
1985年 | 38893篇 |
1984年 | 38501篇 |
1983年 | 36108篇 |
1982年 | 37913篇 |
1981年 | 36122篇 |
1980年 | 34220篇 |
1979年 | 30716篇 |
1978年 | 29452篇 |
1977年 | 27286篇 |
1976年 | 25445篇 |
1975年 | 24461篇 |
1974年 | 23832篇 |
1973年 | 22802篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
52.
53.
54.
55.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
56.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
57.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
58.
59.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
60.